SCHEMBL2858638

SCHEMBL2858638

CCCC1CCC(C2COC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 2/20 0.40
FYN P06241 1/20 0.36
CYP2C9 P11712 1/20 0.35
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
CYP1A2 P05177 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 2/20 0.33
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902321 1.00 TLR4 (0.40) TLR4FYNCYP2C9POLBHPGD
SCHEMBL2852137 1.00 TLR4 (0.40) TLR4FYNCYP2C9POLBHPGD
SCHEMBL4905710 1.00 TLR4 (0.40) TLR4FYNCYP2C9POLBHPGD
SCHEMBL5836344 0.85 TLR4 (0.42) TLR4FYNCYP2C9MEN1KMT2A
SCHEMBL14281259 0.85 PKM (0.47) CYP2C9POLBHPGDMEN1KMT2A
SCHEMBL5836340 0.85 TLR4 (0.42) TLR4FYNCYP2C9MEN1KMT2A
SCHEMBL6697654 0.85 TLR4 (0.42) TLR4FYNCYP2C9MEN1KMT2A
SCHEMBL11019067 0.83 TLR4 (0.41) TLR4FYNCYP2C9MEN1KMT2A
SCHEMBL8217513 0.83 TLR4 (0.41) TLR4FYNCYP2C9MEN1KMT2A
SCHEMBL11019071 0.83 TLR4 (0.41) TLR4FYNCYP2C9MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221114-B2 Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2019-03-05 US disclosed
US-20160200980-A1 LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-07-14 US disclosed
US-20160200980-A1 LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2016-07-14 US disclosed
EP-2258695-B1 CHROMAN DERIVATIVES AND USE THEREOF IN LIQUID CRYSTAL MEDIA MERCK PATENT GMBH (DE) 2013-05-29 EP disclosed
EP-2258695-B1 CHROMAN DERIVATIVES AND USE THEREOF IN LIQUID CRYSTAL MEDIA MERCK PATENT GMBH (DE) 2013-05-29 EP disclosed
EP-2258695-A2 Chroman derivatives and use thereof in liquid crystal media Merck Patent GmbH (DE) 2010-12-08 EP disclosed
EP-2258695-A2 Chroman derivatives and use thereof in liquid crystal media Merck Patent GmbH (DE) 2010-12-08 EP disclosed
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-01-24 US disclosed
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-01-24 US disclosed
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2008-01-24 US disclosed
EP-1831190-A2 CHROMAN DERIVATIVES AND USE THEREOF IN LIQUID CRYSTAL MEDIA Merck Patent GmbH (DE) 2007-09-12 EP disclosed
WO-2006040009-A2 CHROMAN DERIVATIVES AND USE THEREOF IN LIQUID CRYSTAL MEDIA MERCK PATENT GMBH (DE) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200980-A1 LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD2, CNOT1, OCIAD1 TLR4 4014/4885FYN 531/4885CYP2C9 3316/4885
US-10221114-B2 Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device OCIAD2, CNOT1, OCIAD1 TLR4 4014/4885FYN 531/4885CYP2C9 3316/4885
US-20080020148-A1 Chromane Derivatives Method for Production and the Use Thereof C1S, CHRM1, C1R TLR4 2758/4885FYN 1194/4885CYP2C9 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.